2021
Milestone Studies in Breast Cancer Surgery
Chagpar A. Milestone Studies in Breast Cancer Surgery. 2021, 9-17. DOI: 10.1007/978-3-030-73147-2_2.Peer-Reviewed Original ResearchBreast cancer surgeryCancer surgerySentinel node biopsyBreast-conserving surgeryPostoperative cosmetic outcomeBreast cancer managementAxillary dissectionNode biopsyRadical mastectomyLandmark trialsSurgical managementSurgical interventionCosmetic outcomeMargin clearanceBreast cancerCancer managementSurgeryRadiation oncologyMultidisciplinary approachOngoing studiesMilestone studyNumber of advancesMastectomyMorbidityAxilla
2018
Surgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed Complex General Surgical Oncology 2018 DOI: 10.2310/7800.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgerySurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed CGSO Case-Based Reviews 2018 DOI: 10.2310/cgso.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgery
2011
P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11?
Lannin D, Killelea B, Grube B, Horowitz N, Chagpar A. P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11? Cancer Research 2011, 71: p3-07-26-p3-07-26. DOI: 10.1158/0008-5472.sabcs11-p3-07-26.Peer-Reviewed Original ResearchPositive sentinel nodesSentinel node biopsySentinel nodesPositive nodesAxillary dissectionNode biopsyLower axillary recurrence ratePositive sentinel lymph nodesAxillary recurrence rateNode-positive patientsNeo-adjuvant chemotherapyPercentage of patientsNegative sentinel nodesBreast cancer patientsSentinel lymph nodesEligibility requirementsLumpectomy patientsZ11 trialT4 tumorsPositive patientsLymph nodesRecurrence ratePatient populationCancer patientsInstitutional databaseIntraoperative Considerations in Sentinel Lymph Node Biopsy for Breast Cancer
Chagpar A. Intraoperative Considerations in Sentinel Lymph Node Biopsy for Breast Cancer. TouchREVIEWS In Oncology & Haematology 2011, 07: 111. DOI: 10.17925/ohr.2011.07.2.111.Peer-Reviewed Original ResearchSentinel lymph node biopsyLymph node biopsyNode biopsySLN-positive patientsAxillary node dissectionIsolated tumor cellsBreast cancer patientsBreast cancer managementNode dissectionSLN biopsyCancer patientsIntraoperative considerationsSurgical techniqueBreast cancerCancer managementTumor cellsBiopsyPatientsSubject of debateMicrometastasesLymphCancerMainstaySLNsDissection
2009
Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients
Reuter N, Bower M, Scoggins C, Martin R, McMasters K, Chagpar A. Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients. Journal Of Clinical Oncology 2009, 27: 611-611. DOI: 10.1200/jco.2009.27.15_suppl.611.Peer-Reviewed Original ResearchSentinel node biopsyBreast cancer patientsNode biopsySentinel nodesCancer patientsFalse negative rateOptimal timingFN rateSN identification rateMean tumor sizeProspective multicenter studyOverall false-negative rateNon-significant trendCohort of interestMulticenter studyTumor sizeMean ageSulfur colloidBreast cancerSN identificationPatientsInvasive meansNegative rateSignificant financial relationshipHot nodes